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Summary
It is assumed that genetic factors may play a significant role in CKD development. The aim of 
the study was to investigate the role of rs7903146 polymorphism in the TCF7L2 gene in deve-
lopment and progression of non-diabetic chronic kidney disease (CKD). 
109 children and young adults with CKD caused by primary glomerulopathy and tubulointer-
stitial nephropathy, stages 3-5, and their 218 biological parents with no renal dysfunction were 
included in the study. We tested the transmission of alleles of rs7903146 polymorphism in the 
TCF7L2 gene from heterozygous parents to offspring affected with CKD using the transmission/
disequilibrium test. We also analysed whether rs7903146 polymorphism had any impact on 
the loss of glomerular filtration rate. 
The rs7903146 polymorphism in TCF7L2 allele transmission from heterozygous parents to their 
affected children was not different from a random proportion expected for no association, 
in the whole group of subjects, and in the subgroups, depending on CKD aetiology. Lack of 
association between the analysed polymorphism and the loss of glomerular filtration rate was 
found in the total group of patients as well as in the subgroups, regarding the cause of CKD.
This study found no association between rs7903146 polymorphism in the TCF7L2 gene and 
the increased risk for development of CKD caused by primary glomerulopathy and analysed 
tubulointerstitial nephropathy. The progression rate of CKD of non-diabetic aetiology does 
not depend on this polymorphism. 
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teinuria, serum cholesterol levels, and the presence of 
hypertension at two time points, i.e. at the time of CKD 
diagnosis (minimum stage 2 according to K/DOQI) and 
at the time of the study. We also analysed serum cre-
atinine concentrations and their changes during the 
course of the disease and loss of glomerular filtration 
rate (GFR) from the initial diagnosis of CKD (minimum 
stage 2) to the time of the study or the development 
of CKD stage 5, requiring dialysis or transplantation. 
GFR was estimated using the Schwartz formula in chil-
dren and the Cockcroft-Gault formula in young adults. 
Finally, the patients with CKD were divided on the basis 
of their renal function into two groups: (I) patients with 
rapid progression of CKD (n=54), defined as starting 
renal replacement therapy during the 5-year follow-up 
period from the diagnosis of CKD stage 2 and/or with a 
doubling of creatinine level during the follow-up period, 
and (II) patients with slow progression of CKD (n=55), i.e. 
those who had stable renal function. Characteristics of 
the study groups are shown in table 1.
Parents of CKD patients. The mean age of the mothers 
and fathers was 42.33 ± 7.73 and 45.24 ± 7.81 years, 
respectively. None of the parents presented a docu-
mented renal dysfunction, diabetes or impaired fasting 
glucose, while hypertension (defined as systolic blood 
pressure ≥140 mmHg and/or diastolic blood pressure ≥90 
mmHg documented in the medical records on at least 
two separate occasions, or antihypertensive treatment) 
Chronic primary glomerulonephritis was diagnosed on 
the basis of clinical criteria and the renal biopsy in all 
cases. The histopathological findings in renal biopsy 
were: minimal change disease in 3 cases, focal and seg-
mental glomerulosclerosis in 9, mesangial proliferative 
glomerulonephritis in 11, mesangiocapillary glomerulo-
nephritis in 5 and extracapillary glomerulonephritis in 
2 cases. The number of cases of particular histopatholo-
gical types of glomerulopathy was different from typical 
epidemiological data. It is probably due to the fact that 
only patients with clinical diagnostic doubts were quali-
fied for kidney biopsy.
Of the 79 patients with tubulointerstitial nephritis, 16 
had reflux nephropathy, 26 obstructive nephropathy, 
20 chronic pyelonephritis with other urinary system 
abnormalities, and 17 chronic pyelonephritis without 
urinary tract anomalies. The CKD patients were treated 
conservatively (n=51) or required renal replacement 
therapy (haemodialysis, n=17; peritoneal dialysis, n=33; 
transplantation, n=8). The demographic data of the 
patients were as follows: 48 females, 61 males, current 
age 15.42 ± 6.4 (range 0.7-25) years, age at the diagno-
sis of CKD (minimum stage 2) 7.82 ± 6.72 (0.01-22) years, 
CKD duration 8.93 ± 5.59 (0.01-21) years.
The data concerning the history of kidney disease were 
collected from all patients. Many features were taken 
into consideration. To enumerate them: 24-hour pro-
IntroductIon
Chronic kidney disease (CKD) has a complex phenotype, 
which is the consequence of the deleterious influence of 
underlying kidney disease and superimposing inherited 
and environmental factors. It is assumed that genetic 
factors may play a significant role in CKD development 
[7,14]. However, the specific genes responsible for the 
onset and progression of CKD have not been determi-
ned, yet.
In recent years, variants in the transcription factor-7 
like 2 gene (TCF7L2) have been documented to be asso-
ciated with type 2 diabetes (T2DM) in multiple ethnic 
groups [3,10,11,15,16]. The human TCF7L2 gene is loca-
ted on chromosome 10q25.3 and consists of 14 exons and 
13 introns [24]. Most published studies have focused on 
four polymorphic markers: a C-to-T substitution at sin-
gle-nucleotide polymorphism (SNP) rs7903146 of intron 
3, a T-to-C substitution at SNP rs7901695 of intron 3, a 
G-to-T substitution at SNP rs12255372 and a G-to-C sub-
stitution at SNP rs11196205 of intron 4. The TCF7L2 gene 
product is a high-mobility box containing a transcrip-
tion factor that plays a role in activating many genes 
downstream of the Wnt signalling pathway [24]. The 
mechanisms through which TCF7L2 mediates the suscep-
tibility to T2DM remain to be elucidated [13].
Diabetes is a major risk factor for CKD. It is credible that 
variants of the TCF7L2 gene might be important both for 
the development of T2DM and renal disease. The Wnt 
signalling pathway is essential in the developing kidney, 
because it plays a role in regulation of cell proliferation 
and differentiation [6]. Mutations in components of this 
pathway have been identified as the cause of inherited 
kidney diseases [1,23]. The genetic variants of the TCF7L2 
gene may be associated with insulin secretion and insu-
lin sensitivity, impaired glucose metabolism, lipid pro-
file and metabolic syndrome features, factors that are 
also connected with renal alteration phenotype [4,5,22]. 
However, the overall impact of TCF7L2 variants on renal 
function, and in patients with diabetes, is unclear.
Therefore, we investigated, for the first time, whether 
rs7903146 polymorphism in the TCF7L2 gene is associa-
ted with the development and progression of non-diabe-
tic chronic kidney disease.
We applied two different approaches in our work. Firstly, 
a family based study was carried out in families in which 
children were diagnosed with CKD. The family study inc-
luded the transmission/disequilibrium test (TDT), which 
evaluates the transmission frequency of specific alleles 
of a given polymorphism from heterozygous parents to 
offspring affected with the investigated phenotype [8,9]. 
Secondly, we performed a case-control orientated study 
to determine whether polymorphism in the TCF7L2 gene 
influences the progression of renal impairment.
 Materials and Methods
 Patients
One hundred and nine children and young adults with 
CKD, stages 3-5 (according to K/DOQI guidelines [19]), 
due to primary renal disease and their 218 biological 
parents with no renal dysfunction (in total, 327 people) 
were included in the study. We included family trios 
with probands with CKD caused by non-diabetic neph-
ropathy. We excluded family trios with probands with 
CKD attributed to polycystic kidney disease or other 
heritable conditions (for example, Alport’s syndrome), 
traumatic or drug-induced kidney injury, and unknown 
aetiologies. Finally, the causes of CKD were chronic pri-
mary glomerulonephritis (n=30) and tubulointerstitial 
nephritis (n=79). 
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Table 1. Characteristics of the CKD patients
Rapid progression of CKD (n=54) Slow progression of CKD (n=55) P value
Age on examination 
(years)
14.55 ± 7.53
(0.7 - 24)
16.48 ± 5.05
(7.3 – 25)
0.18
Age at CKD diagnosis 
(years)
9.85 ± 6.76
(0.01 - 22)
5.61 ± 6.14
(0.1 - 20)
0.001
Aetiology of CKD: 
--- chronic primary glomerulonephritis
--- chronic tubulointerstitial nephropathy
24
30
6
49
CKD duration
(years)
2.56 ± 1.59
(0.01 – 6)
11.31 ± 4.76
(3 – 22.5)
0.0001
Proteinuria/CKD 
(g/24h)
2.66 ± 4.32
(0 – 25)
0.59 ± 1.53
(0 – 11) 0.00001
Proteinuria/E 
(g/24 h)
1.23 ± 2.16
(0 - 10)
0.59 ± 0.99
(0 – 6.2)
0.32
Serum cholesterol/CKD (mmol/l)
5.55 ± 2.14
(2.1 – 11.96)
4.39 ± 0.95
(2.99 – 8.5)
0.0015
Serum cholesterol /E 
(mmol/l)
4.88 ± 1.8
(2.94 – 11.4)
4.88 ± 0.92
(3.12 – 6.92)
0.22
Presence of hypertension/CKD
 n (%)
27 (50) 15 (27.27) 0.01
Presence of hypertension /E 
n (%)
27 (50) 15 (27.27) 0.01
Data are show as mean ± SD (range) unless specified otherwise.
Parameters were evaluated: at the time of CKD diagnosis, minimum stage 2 by KDOQI (CKD) and at the time of examination (E).346 347
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with non-diabetic nephropathies. Our results indicate 
that the TCF7L2 variant is not involved in the develop-
ment and progression of CKD in the examined cohort. 
We observed that transmission of C and T alleles from 
heterozygous healthy parents to affected offspring was 
not different from the transmission expected for no 
association. Genotype distribution in the group of CKD 
patients (CC: 49.5%, CT: 45%, TT: 5%) was similar to those 
described in healthy populations. Buraczyńska et al. in 
a group of 924 healthy Poles documented the following 
frequencies of rs7903146 genotypes: CC 53%, CT 39%, and 
TT 8% [2]. Similarly, Cauchi et al. in a population of 2499 
healthy French people observed the following distribu-
tion of genotypes: CC 48.3%, CT 42.4%, TT 9.3% [3]. Also 
Munoz et al. [18] among Americans of Caucasian origin 
(n=138) found the frequencies: CC 45%, CT 42% and TT 
11%. 
The data concerning the rs7903146 variant impact on 
kidney injury are limited. Melzer et al. investigated, as a 
secondary outcome, the association of rs7903146 variant 
with renal function among elderly T2DM patients [16]. 
They found that T allele carriers (n=32) had significantly 
worse renal function, measured by 24-hour creatinine 
clearance. However, the small number of patients with 
renal complications limited that study. Buraczyńska et 
al. in a large group of Polish patients with T2DM found 
an association between SNP and diabetic nephropa-
thy (diagnosed as persistent albuminuria ≥300 mg/24 
h), especially in patients with an early onset of diabe-
tes [2]. Results of 3 large population-based trials – ARIC, 
affected children was not different from a random pro-
portion expected for no association, in the whole group 
of subjects and in the subgroups, depending on CKD 
aetiology (chronic primary glomerulonephritis, chronic 
interstitial nephropathy) [table 3].
Moreover, lack of association between the analysed 
polymorphism and the loss of glomerular filtration rate 
(rapid vs slow progression of the disease) was found in 
the total group of patients as well as in the subgroups, in 
regard to the cause of CKD [table 4].
The values of 24-hour proteinuria, serum cholesterol 
concentration and hypertension were not different 
between subgroups of CKD patients, regarding the ana-
lysed polymorphism genotypes CC, CT, TT (data not 
shown). 
dIscussIon
The association between the rs7903146 TCF7L2 gene 
polymorphism and T2DM has been confirmed in numer-
ous populations, including Polish [13,17,24]. It is widely 
known that diabetes is the most frequent cause of CKD 
in the adult population, but in contrast, non-diabetic 
nephropathies are more prevalent in children and young 
adolescents.
 In the present study for the first time we have analysed 
the potential association of rs7903146 polymorphism in 
the TCF7L2 gene with CKD in a young population affected 
disorders and hypertension) in CKD progression in rela-
tion to the studied polymorphism.
Statistical analysis 
Basic characteristics for qualitative parameters are 
shown as absolute numbers and percentages. Quantita-
tive data are expressed as the mean ± standard deviation 
(SD) from the mean. The normality of the distribution 
of the continuous variables was checked by the Shapiro-
-Wilk test. In the statistical analysis, Freeman-Halton 
test, Mann-Whitney U test, and chi-squared test were 
used. 
The TDT was used in the family-based study. The obse-
rved transmission was compared with the transmission 
expected for no association (i.e. random transmission, 
50:50%), using McNemar’s test (Ewens and Spielman, 
1995, 2005). Alleles transmitted significantly greater 
than 50% of the time to affected offspring provide evi-
dence of disease association. P<0.05 was considered 
significant. All calculations were performed using Sta-
tistica 7.1.
 results 
The results are shown in tables 2-4. The differences in 
genotype frequency between patients with chronic pri-
mary glomerulonephritis (GN group) and chronic inter-
stitial nephropathies (IN group) were not significant 
(chi-square test; p=0.82) [table 2].
The rs7903146 polymorphism in the TCF7L2 gene alleles 
transmission from heterozygous parents to their 
was present in 3.6% (n=4) and 9.8% (n=11) of the exami-
ned mothers and fathers, respectively.
The parents and children over the age of 16 gave their 
written informed consent. The study protocol adhered 
to the Declaration of Helsinki of 1975 as revised in 1997, 
and was approved by the Ethics Committee of Wroclaw 
Medical University. 
Methods 
Rs7903146 polymorphism in the TCF7L2 gene was geno-
typed in family-based trio members: patients affected 
with CKD and both their parents. Venous blood was col-
lected into EDTA-containing tubes. Genomic DNA was 
isolated from peripheral blood white blood cells using 
a standard salting-out process (Epicentre Technologies, 
USA). The rs7903146 polymorphism in the TCF7L2 gene 
was genotyped using the PCR-based RFLP method. The 
region was amplified with the following primers: F: 5’- 
GAG AGC TAA GCA CTT TTT AGg TA -3’ R: 5’- CTG ACA 
TTG ACT AAG TTA CTT GC - 3’. The 113 base pair PCR 
product was digested with RsaI restriction enzyme (New 
England Biolabs, USA). The C allele creates a restriction 
site and gives two fragments of 91 and 22 base pairs after 
digestion with the restriction enzyme.
We tested the transmission of alleles of rs7903146 poly-
morphism in the TCF7L2 gene from heterozygous parents 
to offspring affected with CKD using TDT. We also ana-
lysed whether rs7903146 polymorphism in the TCF7L2 
gene had any impact on the loss of glomerular filtration 
rate (rapid vs slow CKD progression). Additionally, we 
evaluated the role of selected factors (proteinuria, lipid 
Table 2. The frequency of genotypes and allele of rs7903146 polymorphism in the TCF7L2 in the groups of the CKD patients and their parents
All CKD patients
(n=109)
GN
(n=30)
IN
(n=79)
GENOTYPE n (%):
 CC 54 (49.5) 15 (50) 39 (49.4)
 CT 49 (45.0) 14 (46.7) 35 (44.3)
 TT 6 (5.5) 1 (3.3) 5 (6.3)
ALLELE n (%)
 C 157 (72.02) 44 (73.3) 113 (71.5)
 T 61 (27.98) 16 (26.7) 45 (28.5)
Parents
of all children
(n=218)
Parents
of GN children
(n=60)
Parents
of IN children
(n=158)
GENOTYPE n (%)
CC 115 (52.75) 31 (51.67) 84 (53.16)
CT
86 (39.45)
22 (36.67) 64 (40.51)
TT 17 (7.8) 7 (11.66) 10 (6.33)
ALLELE n (%)
C 316 (71.48) 84 (70) 232 (73.42)
T 120 (27.52) 36 (30) 84 (26.58)
GN - chronic primary glomerulonephritis. IN –chronic tubulointerstitial nephropathy.
Table 3. The transmission of alleles of rs7903146 polymorphism in  TCF7L2 gene from heterozygous parents to offspring with CKD (transmission/disequilibrium test)
All patients GN IN
The number of total transmitted alleles 90 22 64
C transmitted 44 11 29
T transmitted 46 11 35
p 0.83  1  0.45 
GN - chronic primary glomerulonephritis, IN –chronic tubulointerstitial nephropathy.
Table 4. Comparisons of allelic and genotypic frequencies between subgroups of the CKD patients 
Genotype
Slow progression of 
CKD (n=55)
n (%)
Rapid progression 
of CKD
(n=54)
n (%)
GN
(n=30)
IN
(n=79)
Slow progression 
of CKD
(n=6)
n (%)
Rapid progression 
of CKD
(n=24)
n (%)
Slow progression 
of CKD
(n=49)
n (%)
Rapid
progression of CKD
(n=30)
n (%)
CC 29 (52.73) 25 (46.3) 4 (66.67) 11 (45.83) 25 (51.02) 15 (50)
CT 22 (40) 27 (50) 2 (33.33) 12 (50) 20 (40.82) 14 (46.67)
TT 4 (7.27) 2 (3.7) 0 (0) 1 (4.17) 4 (8.16) 1 (3.33)
p=0.48  p=0.87 
Allele n (%) n (%) n (%) n (%) n (%)
n (%)
C 80 (72.7) 77 (71.3) 10 (83.3) 34 (70.8) 70 (71.4) 44 (73.33)
T 30 (27.3) 31 (28.7) 2 (16.7) 14 (29.2) 28 (28.6) 16 (26.67)
p=0.81  p=0.38  p=0.97 
GN - chronic primary glomerulonephritis, IN – chronic tubulointerstitial nephropathy.348 349
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action, including damage and endothelial dysfunction 
[16,22]. Körner et al., who investigated different vari-
ants of the TCF7L2 gene in a cohort of obese children, 
noted the significant association with glucose metabo-
lism alterations in T allele carriers, which was unrelated 
to body mass index, age and gender [12]. On the other 
hand, Melzer et al. found that T allele is connected with 
the protective lipid profile (higher serum concentra-
tion of HDL cholesterol, and lower level of triglycerides) 
in the overall population of Italian elderly people [16]. 
The association was not linked to carbohydrate metabo-
lism parameter values. These authors also documented 
that T allele carriers had lower incidence of metabolic 
syndrome, defined as hypertension, abdominal obesity, 
high concentrations of serum triglycerides and low lev-
els of HDL cholesterol. The various factors, specified 
above, associated with the variant of the TCF7L2 gene, 
are simultaneously well-known features that modify the 
course of CKD [20,21]
 Our study has several limitations. By using the trans-
mission/disequilibrium test, the impact of population 
stratification was excluded, but other forms of selection 
bias, e.g. associated with patients’ survival, could have 
been introduced. The number of examined families was 
relatively small, which is due to low prevalence of child-
hood CKD as compared to adult CKD. There are evident 
difficulties in obtaining consent and getting samples 
from patients and both their parents. Finally, although 
in every child the cause of CKD was of non-diabetic ori-
gin, the spectrum of diseases was not homogeneous, 
including glomerulopathies and tubulointerstitial 
nephropathies. 
In conclusion, rs7903146 polymorphism of the TCF7L2 
gene does not have an impact on the development of 
CKD caused by primary glomerulopathy and analysed 
tubulointerstitial nephropathy, which is confirmed by 
the lack of a significant difference in the transmission 
of these polymorphism alleles in examined family-based 
trios. The lack of association between rs7903146 poly-
morphism and the rate of renal function loss in the 
investigated patients suggests that the CKD progress 
rate does not depend on this polymorphism. The ques-
tion whether rs7903146 polymorphism in the TCF7L2 
gene is involved in progression of non-diabetic CKD still 
remains an open issue.
FHS and HAPI – suggest that some variants in the TCF7L2 
gene are associated with reduced kidney function and 
CKD progression overall and among subjects without 
diabetes [13]. The T allele of rs7903146 polymorphism 
was significantly associated with lower estimated GFR 
(in FHS and HAPI studies) and higher serum cystatin C 
level (FHS study). The data mentioned above, although 
highly significant for the description of TCF7L2 gene 
variant frequency in kidney diseases, could not be com-
pared with our results due to different study designs 
(population-based case-control study vs family-based 
study), race variability of examined populations, renal 
function evaluation by different formulas, estimation of 
CKD progression and finally diverse clinical phenotypes 
of the disease. 
We applied a family-based study to avoid the potential 
bias of case-control studies. The TDT is a powerful statis-
tical test to detect linkage between the marker allele and 
susceptibility to the disease. The group we examined 
was ethnically homogeneous. Moreover, the members of 
families enrolled in the study had normal carbohydrate 
metabolism and all the children suffered from a non-di-
abetic nephropathy. 
The results of our investigation did not show a rela-
tionship between the rs7903146 polymorphism and the 
rate of glomerular filtration decline. There was also no 
difference in the values of 24-hour proteinuria, serum 
cholesterol level and presence of hypertension, known 
risk factors of CKD progression, between the subjects 
with different genotypes TT, CT and CC. Similarly, in 
the population-based ARIC study an association of this 
gene polymorphism with eGFR was not found. Both ARIC 
and FHS studies did not show any relationship between 
rs7903146 polymorphism and the degree of albumin-
uria [13]. The association between rs7903146 polymor-
phism and CKD progression among individuals without 
diabetes, found in population-based cohorts, may be the 
result of the influence of previously undetected diabetes 
and impaired glucose metabolism. It is therefore plausi-
ble that a mutation could mediate reduced kidney func-
tion only via its effects on hyperglycaemia. Assuming 
further that the TCF7L2 variant increases the risk for CKD 
through other renal specific mechanisms, the results of 
the presented studies are ambiguous. It was confirmed 
that rs7903146 polymorphism of the TCF7L2 gene may 
influence insulin secretion and modify the effects of its 
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